NEW YORK — The US Food and Drug Administration last month granted Emergency Use Authorization for DiaSorin's Liaison SARS-CoV-2 Ag SARS-CoV-2 antigen test.
The chemiluminescent immunoassay is designed to detect SARS-CoV-2 nucleocapsid protein antigen in nasopharyngeal swab samples collected by healthcare providers using Copan Diagnostics' universal transport media and direct anterior nasal swab collected without transport media.